PL355892A1 - 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor - Google Patents

4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor

Info

Publication number
PL355892A1
PL355892A1 PL00355892A PL35589200A PL355892A1 PL 355892 A1 PL355892 A1 PL 355892A1 PL 00355892 A PL00355892 A PL 00355892A PL 35589200 A PL35589200 A PL 35589200A PL 355892 A1 PL355892 A1 PL 355892A1
Authority
PL
Poland
Prior art keywords
carboxyamino
tetrahydroquinoline
ethyl
crystal
cetp inhibitor
Prior art date
Application number
PL00355892A
Other languages
English (en)
Polish (pl)
Inventor
Douglas John Meldrum Allen
Troy Anthony Appleton
Lyle Robinson Brostrom
Derek Lawrence Tickner
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of PL355892A1 publication Critical patent/PL355892A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
  • Quinoline Compounds (AREA)
PL00355892A 1999-11-30 2000-11-14 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor PL355892A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16805199P 1999-11-30 1999-11-30
PCT/IB2000/001650 WO2001040190A1 (en) 1999-11-30 2000-11-14 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor

Publications (1)

Publication Number Publication Date
PL355892A1 true PL355892A1 (en) 2004-05-31

Family

ID=22609901

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00355892A PL355892A1 (en) 1999-11-30 2000-11-14 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor

Country Status (28)

Country Link
EP (1) EP1246804A1 (es)
JP (1) JP2003515592A (es)
KR (1) KR20020058057A (es)
CN (1) CN1402711A (es)
AP (1) AP2002002531A0 (es)
AU (1) AU1048801A (es)
BG (1) BG106854A (es)
BR (1) BR0015836A (es)
CA (1) CA2392979A1 (es)
CO (1) CO5271716A1 (es)
EA (1) EA200200510A1 (es)
EC (1) ECSP003792A (es)
EE (1) EE200200277A (es)
GT (1) GT200000199A (es)
HU (1) HUP0203521A2 (es)
IL (1) IL149097A0 (es)
IS (1) IS6338A (es)
MA (1) MA26845A1 (es)
MX (1) MXPA02005354A (es)
NO (1) NO20022558D0 (es)
OA (1) OA12099A (es)
PA (1) PA8506301A1 (es)
PE (1) PE20010904A1 (es)
PL (1) PL355892A1 (es)
TN (1) TNSN00231A1 (es)
TR (1) TR200201446T2 (es)
UY (1) UY26454A1 (es)
WO (1) WO2001040190A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
SK15172003A3 (en) 2001-06-21 2004-11-03 Pfizer Prod Inc Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
GT200200170A (es) * 2001-09-28 2003-05-23 Preparacion de inhibidor de cetp anhidro
EP1469832B2 (en) 2002-02-01 2016-10-26 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
BR0307333A (pt) * 2002-02-01 2004-12-07 Pfizer Prod Inc Métodos para a preparação de dispersões homogéneas de fármacos sólidos amorfos atomizados utilizando um sistema de secagem por pulverização
EP1920766B1 (en) * 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
EP1533292B1 (en) 2002-08-30 2007-02-14 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
EA011385B1 (ru) 2002-10-04 2009-02-27 Миллениум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
DE60323536D1 (de) 2002-12-20 2008-10-23 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
EA200501376A1 (ru) * 2003-03-28 2006-04-28 Пфайзер Продактс Инк. Производные 1,2,4-замещённых 1,2,3,4-тетрагидро- и 1,2-дигидрохинолинов и 1,2,3,4-тетрагидрохиноксалина в качестве ингибиторов сетр для лечения атеросклероза и тучности
WO2005011635A2 (en) 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
US7749992B2 (en) 2003-10-08 2010-07-06 Eli Lilly And Company Compounds and methods for treating dislipidemia
WO2005100298A1 (en) * 2004-04-13 2005-10-27 Merck & Co., Inc. Cetp inhibitors
EP1761521A1 (en) * 2004-06-24 2007-03-14 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
US20070149567A1 (en) * 2004-09-23 2007-06-28 Pfizer Inc Quinoline compounds
KR20070114762A (ko) 2005-02-24 2007-12-04 밀레니엄 파머슈티컬스 인코퍼레이티드 염증 질환 치료를 위한 ｐｇｄ2 수용체 길항제
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2008112166A2 (en) 2007-03-09 2008-09-18 Indigene Pharmaceuticals Inc. Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
AR077208A1 (es) 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
ES2825675T3 (es) 2014-07-30 2021-05-17 Hoffmann La Roche Marcadores genéticos para predecir la reactividad al tratamiento con un agente que aumenta las HDL o que imita las HDL

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
AU5731098A (en) * 1997-02-03 1998-08-25 American Home Products Corporation 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
MXPA02005354A (es) 2002-12-11
PE20010904A1 (es) 2001-09-10
MA26845A1 (fr) 2004-12-20
EE200200277A (et) 2003-10-15
EP1246804A1 (en) 2002-10-09
ECSP003792A (es) 2002-04-23
TR200201446T2 (tr) 2002-11-21
UY26454A1 (es) 2001-07-31
CA2392979A1 (en) 2001-06-07
AP2002002531A0 (en) 2002-06-30
AU1048801A (en) 2001-06-12
EA200200510A1 (ru) 2002-10-31
JP2003515592A (ja) 2003-05-07
CO5271716A1 (es) 2003-04-30
BR0015836A (pt) 2002-08-06
OA12099A (en) 2006-05-04
WO2001040190A1 (en) 2001-06-07
TNSN00231A1 (fr) 2002-05-30
CN1402711A (zh) 2003-03-12
HUP0203521A2 (hu) 2003-02-28
PA8506301A1 (es) 2002-08-26
KR20020058057A (ko) 2002-07-12
IL149097A0 (en) 2002-11-10
IS6338A (is) 2002-04-12
GT200000199A (es) 2002-05-23
NO20022558L (no) 2002-05-29
NO20022558D0 (no) 2002-05-29
BG106854A (bg) 2002-12-29

Similar Documents

Publication Publication Date Title
PL355892A1 (en) 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor
IL173393A0 (en) 4-carboxyamino-2- substituted-1,2,3,4- tetrahydroquinolines as cetp inhibitors
SI1114033T1 (en) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as cetp inhibitors
IL141388A0 (en) 4-amino substituted-2- substituted 1,2,3,4- tetrahydroquinolines as cetp inhibitors
GB9904103D0 (en) Quinoline derivatives
MXPA01013406A (es) Compuestos inhibidores de vla-4.
ZA200203095B (en) Biphenyl derivatives used as NHE-3 inhibitors.
IL150114A0 (en) Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
IL149424A0 (en) 14,15-beta-methylene substituted androgens
GB9916392D0 (en) Novel process
SI1114031T1 (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
GB9920146D0 (en) Novel process
GB9919001D0 (en) Novel process
GB9921243D0 (en) Novel process
CA88264S (en) Sunglasses
CA88270S (en) Sunglasses
CA88265S (en) Sunglasses
GB9904102D0 (en) Quinoline derivatives
GB9904105D0 (en) Quinoline derivatives
ZA200109203B (en) VLA-4 inhibitor compounds.
AU141767S (en) Sunglasses
AU141772S (en) Sunglasses
AU141771S (en) Sunglasses
AU141770S (en) Sunglasses
AU137566S (en) Sunglasses

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)